BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2515813)

  • 1. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations.
    Aeschlimann A; Meyer O; Bourgeois P; Haim T; Belmatoug N; Palazzo E; Kahn MF
    Ann Rheum Dis; 1989 Dec; 48(12):992-7. PubMed ID: 2515813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-Scl-70 antibodies in systemic scleroderma].
    Le Thi Huong ; Sauvaget F; Johanet C; De Gennes C; Raguin G; Abuaf N; Blétry O; Guillevin L; Homberg JC; Godeau P
    Ann Dermatol Venereol; 1990; 117(2):103-7. PubMed ID: 2111650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological markers in progressive systemic sclerosis: clinical correlations.
    Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
    Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population.
    Catoggio LJ; Skinner RP; Maddison PJ
    Rheumatol Int; 1983; 3(1):19-21. PubMed ID: 6412349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinuclear antibodies in progressive systemic sclerosis.
    Riboldi P; Asero R; Origgi L; Crespi S; Meroni PL; Sguotti C; Sabbadini MG
    Clin Exp Rheumatol; 1985; 3(3):205-11. PubMed ID: 3902296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
    J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinuclear antibodies detected by indirect immunofluorescence on HEp2 cells and by immunoblotting in patients with systemic sclerosis.
    Briolay J; Gioud M; Monier JC; Rodde JL; Cohen J; Roux B; Kaliss B
    Autoimmunity; 1989; 2(2):165-76. PubMed ID: 2491600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CREST syndrome: a distinct serologic entity with anticentromere antibodies.
    Fritzler MJ; Kinsella TD
    Am J Med; 1980 Oct; 69(4):520-6. PubMed ID: 6968511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease.
    Goldman JA
    Ann Rheum Dis; 1989 Sep; 48(9):771-5. PubMed ID: 2802800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.
    Cruz M; Mejia G; Lavalle C; Cortes JJ; Reyes PA
    Clin Rheumatol; 1988 Mar; 7(1):80-6. PubMed ID: 3261675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibodies to extractable nuclear antigen polypeptides: detection and its clinical significance].
    Xu YH
    Zhonghua Yi Xue Za Zhi; 1992 Sep; 72(9):541-3, 573. PubMed ID: 1338517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients.
    Franceschini F; Cavazzana I; Generali D; Quinzanini M; Viardi L; Ghirardello A; Doria A; Cattaneo R
    J Rheumatol; 2002 Jul; 29(7):1393-7. PubMed ID: 12136894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical significance of anti-ENA antibodies and anticentromere antibody (ACA) in patients with sclerodermatous skin changes and Raynaud's phenomenon].
    Uchida K; Kondo H; Kashiwazaki S
    Ryumachi; 1984 Aug; 24(4):241-9. PubMed ID: 6334895
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antinuclear, anticentromere and anti-ScL-70 antibodies in rheumatic diseases].
    Ivanova SM; Melkumova KL; Il'in KV; Riazantseva TA; Piven' VA; Speranskiĭ AI
    Lab Delo; 1990; (6):50-3. PubMed ID: 1699041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin G subclass distribution of autoantibodies in systemic sclerosis, primary biliary cirrhosis, and overlap syndromes.
    French MA; Bernstein RM
    Ann Rheum Dis; 1987 Jun; 46(6):436-40. PubMed ID: 3115201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of anti-double stranded DNA idiotype in mixed connective tissue disease and progressive systemic sclerosis.
    Kubota T; Kanai Y
    Bull Tokyo Med Dent Univ; 1989 Jun; 36(2):13-8. PubMed ID: 2789110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations.
    Błaszczyk M; Jarzabek-Chorzelska M; Jabłońska S; Chorzelski T; Kołacińska-Strasz Z; Beutner EH; Kumar V
    Br J Dermatol; 1990 Oct; 123(4):421-30. PubMed ID: 2128868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-Scl-70 and anti-centromere autoantibodies. Biological markers of 2 forms of systemic scleroderma].
    Johanet C; Agostini MM; Vayssairat M; Abuaf N
    Presse Med; 1989 Feb; 18(5):207-11. PubMed ID: 2522207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting.
    Kallenberg CG; Wouda AA; Hoet MH; van Venrooij WJ
    Ann Rheum Dis; 1988 Aug; 47(8):634-41. PubMed ID: 3261966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nuclear antibodies as serologic markers in progressive systemic scleroderma].
    Lakomek HJ; Guldner HH; Bautz FA; Goerz G; Kind P; Mensing H; Krüskemper HL
    Hautarzt; 1987 Feb; 38(2):63-9. PubMed ID: 3106261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.